Lipids and Cholesterol Archive
Patients with statin intolerance had a 36% higher rate of recurrent MI compared to those with high statin adherence.
Women experienced the same CV benefits in statin trials, despite having slightly elevated on-treatment LDL cholesterol.
Risk of both ischemic stroke and coronary heart disease was elevated with high triglycerides and low high-density lipoprotein cholesterol.
Low levels of low-density lipoprotein cholesterol appear to be well tolerated on alirocumab therapy.
Data from 14 phase 2 and 3 studies were pooled to assess the safety of lowering LDL cholesterol with alirocumab.
Too few American young adults are receiving needed statin medications, according to findings published in JAMA Cardiology.
Fenofibrate therapy may reduce cardiovascular disease (CVD) in statin-treated patients with diabetes and dyslipidemia.
Oxidized low-density lipoprotein (ox-LDL) as a proxy for oxidative stress is associated with metabolic syndrome and its components.
Healthier diets may be a factor in the ongoing decline in cholesterol levels for Americans.
Women and minorities with HIV are less frequently tested for dyslipidemia, according to a new study from IDWeek 2016.
A mean 51% reduction in LDL cholesterol was seen in the group assigned to the 300 mg dose of inclisiran.
An analysis of more than 80,000 Chinese participants found that all alcohol consumption slowed the decline of HDL cholesterol in the body.
Antihypertensive drugs and rosuvastatin did not prevent or worsen cognitive decline in those at intermediate risk for CVD.
For patients with type 1 diabetes, the correlation between PCSK9 and LDL cholesterol is only seen in the highest tertile for HbA1c.
As children age, the impact of changes in HbA1c and BMI on LDL cholesterol and non-HDL cholesterol levels increases.
Low and high levels of HDL cholesterol are linked to increased mortality risk, according to a study published in the Journal of the American College of Cardiology.
Screening for hypercholesterolemia is feasible at routine child immunization visits in primary care practices.
Statins can interact with other drugs prescribed for cardiovascular disease, but there are ways to navigate the issue.
Levels of triglycerides and HDL cholesterol are independent risk factors for chronic diabetic kidney disease in type 2 diabetes.
LDL cholesterol-lowering genetic variants are associated with increased risk of type 2 diabetes, according to a meta-analysis published in JAMA.
Blacks have increased incidence of hypertension, diabetes, and dyslipidemia but not atrial fibrillation.
Treatments other than statins also can effectively reduce cardiovascular (CV) risk, according to a review and meta-analysis published in the JAMA.
At week 52, all subgroups saw a change in levels of low-density lipoprotein cholesterol.
The researchers found larger absolute benefits for prolonged therapy and also noted that benefits outweigh rare cases of adverse events.
For patients with primary hypercholesterolemia, fixed-dose combination of ezetimibe plus rosuvastatin is more effective than rosuvastatin alone.
For patients with familial hypercholesterolemia or atherosclerotic cardiovascular disease, PCSK9 inhibitor use is not cost-effective.
The US Preventive Services Task Force (USPSTF) has concluded that the evidence is currently insufficient to weigh the balance of benefits and harms of screening for lipid disorders in children and adolescents (aged 20 years or younger).
All but one type of statin was associated with a dose-dependent neurprotective benefit against Parkinson's.
Routinely measured lipid fractions may be associated with the risk of coronary artery disease (CAD) and diabetes.
Evolocumab will now be available via the Pushtronex system™, designed to deliver 420 mg in a single dose.
Patients with heterozygous familial hypercholesterolemia have a significantly increased risk for coronary heart disease and atherosclerotic cardiovascular disease.
For children with type 1 diabetes, the negative influence of celiac disease on HDL cholesterol can be improved by adherence to a gluten-free diet.
Risk for cardiovascular events was significantly lower among patients with moderate LDL levels, compared to patients with high LDL levels.
Particulate matter may alter metabolism of glucose and lipids, especially among those with diabetes.
Increased risk for cardiovascular events and all-cause mortality were observed for patients with type 2 diabetes.
Robert Eckel, MD, discusses lipid management in the era of PCSK9 inhibitors at AACE 2016.
Heterozygous mutation carriers have lower levels of non-HDL cholesterol and reduced risk for coronary artery disease.
Cardiovascular disease risk is higher when low HDL cholesterol is accompanied by high triglycerides and LDL cholesterol.
The first generic version of Crestor (rosuvastatin calcium) tablets was recently approved by the Food and Drug Administration (FDA).
Treatment is important for primary prevention even without history of cardiovascular disease, researchers said.
Greater LDL cholesterol reductions for rosuvastatin 10 mg to 40 mg vs equal and double doses of atorvastatin and simvastatin.
Children who exhibited at least 4 unhealthy behaviors were more likely to be obese and have unfavorable cholesterol levels.
Evacetrapib did lower low-density lipoprotein cholesterol in high vascular risk patients, but did not reduce major cardiovascular events.
Having both diseases raises a patient's chances for developing diabetes.
Remnant cholesterol predicted coronary artery disease events even after adjustment for presence and extent of disease.
Adolescents with autism spectrum disorder appear to be more likely to develop the disease.
Researchers found that roughly 834 500 Americans have the inherited condition.
Two studies show carriers of the ANGPTL4 variant have better lipid levels and a lower likelihood of coronary artery disease.
Adverse effects on glucose tolerance, insulin sensitivity, blood lipids observed in Mexican-Americans.
Some clinical departments tend to undertreat when prescribing statins, according to a study published in the Journal of Clinical Pharmacy and Therapeutics.
Lipid-lowering therapy with ezetimibe plus simvastatin is associated with improved clinical outcomes, with a reduction in total primary end point events.
For patients with type 2 diabetes, a statin plus extended-release niacin lowers apolipoprotein B-48 (apoB-48) concentration compared with a statin alone.
There appears to be insufficient evidence for lipid screening in children, while the recommendations for statins varies with age and risk.
In a 10-5 vote, an FDA panel recommended against expanding indications for ezetimibe and ezetimibe/simvastatin.
Follicle-stimulating hormone may interact with its receptors and lead to elevated LDL cholesterol in postmenopausal women.
Researchers noted an improvement in lipid profile for nutraceuticals alone or in combination in statin-intolerant patients.
American Academy of Pediatrics guidelines reflect concerns about obesity, suicide, and more.
Simvastatin plus ezetimibe is linked to lower risk for cataract development vs placebo.
Only half of those who should be using medications to lower cholesterol actually are.
Adults aged 40 to 59 years did not achieve Healthy People 2020 goals during 2011 to 2014.
Rosuvastatin may be more effective than atorvastatin for reversion of coronary atherosclerotic plaques.
LDL cholesterol and HbA1c goals were maintained after veterans with type 2 diabetes were discharged from pharmacist-managed clinic.
A recent study suggests that disruptive sleep patterns throughout the week could lead to increased risk for diabetes and heart disease.
Disclosing genetic risk information resulted in lower LDL cholesterol levels in patients at risk for coronary heart disease.
Cooperation is key to program's success, but the benefits are modest.
Only one-third to one-half of eligible Hispanic patients studied are taking statins or other lipid-lowering therapies.
Trends in non-statin lipid-lowering therapy use impacted by negative clinical trial results
Altered tendon structure or pain is linked to higher total cholesterol, LDL cholesterol, and triglycerides.
Increased HDL cholesterol during menopausal transition linked to greater carotid intima-media thickness.
Obesity linked to elevated absolute values of circulating CD3+ and CD4+ cells.
Findings in patients with coronary artery disease on statin therapy after undergoing first PCI.
New application seeks approval of a single-injection option for the monthly administration of evolocumab.
However, more research is needed to understand how different bacteria affect risk factors for heart disease.
Number and intensity of crises reduced in association with reduction in total, LDL cholesterol.
Newly FDA-approved Repatha and Praluent currently cost more than $14,000 per year.
Higher numbers of insured leading to more treatment of hypertension, high cholesterol and diabetes.
Reduction in sugar-sweetened beverage intake over 12 months linked to increase in plasma HDL.
Meta-analysis shows superior treatment effects on inflammation, cardiac function.
Possible metabolic mechanism includes activation of AMPK, FADS suppression.
Vitamin D supplementation in obese adolescents did not benefit their cardiovascular health or diabetes risk.
Concerns about overtreatment, overlooking of cholesterol levels.
For calculated LDL cholesterol of 30 mg/dL, 95% CI was 24 mg/dL to 60 mg/dL.
Speakers address the different guidelines for management of dyslipidemia and discuss how best to incorporate them into clinical practice.
Even with regular exercise, sitting for long periods is linked to higher blood glucose and cholesterol levels.
The drug, ISIS 304801, demonstrates role of apolipoprotein C-III in managing triglycerides
Combination therapy linked to greater coronary plaque regression in Japanese patients.
The FDA has approved the first PCSK9 inhibitor to treat certain adults with high cholesterol.
Elimination of five modifiable risk factors could cut the number of cardiovascular deaths.
There were higher transfers of unesterified and esterified cholesterol to HDL in exercisers vs. sedentary women.
Key features include elimination of treatment targets and additional testing only when rationale clear.
Findings in older men with high cholesterol and low testosterone.
Researchers noted an increase in free fatty acids and triglycerides and a decrease in LDL and HDL cholesterol.
An FDA advisory committee has recommended approval of alirocumab (Praluent, Regeneron) for treatment of hypercholesterolemia.
Lowering of LDL cholesterol levels, improved CV outcomes for simvastatin plus ezetimibe.
Patients taking a statin had lower mortality risk in weeks after the surgery, researchers say.
Older patients had one-third lower risk for stroke when taking statins or fibrates.
Treatment of iron deficiency anemia was linked to improvements in vitamin B12, folate and lipids.
The progression of prostate cancer appeared to be slowed in those taking statins.
Although decreases have been seen in the last decade, many people still remain at risk.
Mixed results indicate that while the mortality rate for "Baby Boomers" is declining, many are taking cardiovascular drugs or have diabetes.
Endocrinology Advisor Articles
- Predictors of Success for Insulin-to-Liraglutide Switch for Type 2 Diabetes
- Efficacy and Safety of Alirocumab in Diabetes Mellitus
- Safety of DPP-IV Inhibitor, Cardiovascular Events After ACS in Type 2 Diabetes
- Transgender Youth Not Willing to Delay Hormone Therapy for Fertility Preservation
- Pre-Pregnancy Programs May Improve Outcomes in Women With Type 2 Diabetes
- Diabetes Treatments
- Metformin May Decrease Colorectal Cancer Risk Among Males With Diabetes
- SGLT2 Inhibitor, GLP-1 Receptor Agonist Combination Treatment for Type 2 Diabetes: Expert Insights
- Semaglutide May Induce Weight Loss in Type 2 Diabetes Despite BMI
- FDA Clears Omnipod DASH System for Diabetes Management
- IV Fluid Infusion Rates Do Not Affect Pediatric DKA Neurologic Outcomes
- Effect of Fructose, Allulose on Postprandial Glucose Regulation in Type 2 Diabetes
- Psychiatric Morbidity Decreased After Assisted Reproductive Technology Treatment
- Fenofibrate Improves Cholesterol Levels in Type 2 Diabetes
- Sex Hormone Levels May Affect Postmenopausal Heart Disease Risk